Evidence map›Paper›PMID 30051260›Full record

ReviewClinical reviews in allergy & immunology2018

Autoimmunity in 2017.

Carlo Selmi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical reviews in allergy & immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Carlo SelmiDivision of Rheumatology and Clinical Immunology, Humanitas Research Hospital, via A. Manzoni 56, 20089 Rozzano, Milan, Italy. carlo.selmi@unimi.it.ORCID http://orcid.org/0000-0002-0323-0376

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The number of peer-reviewed articles published during the 2017 solar year and retrieved using the "autoimmunity" key word increased significantly compared to 2016 while maintaining a stable share within the immunology field, following years with alternated fortunes. A detailed arbitrary analysis of the published articles in leading immunology and autoimmunity journals provides a privileged viewpoint on the current trends of research from both basic and clinical studies. Indeed, we are observing that major steps forward are found for rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis, among others. In particular, the new data on pregnancy success in lupus or biomarkers in systemic sclerosis are believed to change our management of these systemic conditions. In the case of rheumatoid arthritis, we have obtained data with significant implications in the understanding of the disease pathogenesis (as in the case of platelets), disease phenotyping, and new treatment options. Furthermore, the exponential growth of treatment options for cancer based on immune checkpoint modulation is paralleled by the need to address the potential autoimmunity side effects while taking advantage of new information obtained in paraneoplastic autoimmune conditions. Cumulatively, 2017 has been a very exciting year for autoimmune diseases, and we foresee that most of the data discussed herein will be followed by more extensive studies in the upcoming months.

Indexed as

AutoimmunityAnimalsAutoantibodiesAutoimmune DiseasesBlood PlateletsHumansImmune ToleranceNeoplasmsTh17 CellsAutoantibodiesAutoantibodyImmune checkpoint inhibitorsImmune tolerancePlateletTh17

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.